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1  | INTRODUC TION
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/thre-
onine kinase and an atypical member of the cyclin-dependent kinase 
family. Unlike most of the conventional cyclin-dependent kinases, 
Cdk5 is predominantly expressed in neurons and can be activated by 
binding of non-cyclin activators p35 or p39. Cdk5 plays a crucial role 
in regulating the cytoarchitecture of the central nervous system; 
 
Received: 25 February 2020  |  Revised: 20 March 2020  |  Accepted: 26 March 2020
DOI: 10.1111/jcmm.15268  
O R I G I N A L  A R T I C L E
Retrospective assessment of cyclin-dependent kinase 5 mRNA 
and protein expression and its association with patient survival 
in breast cancer
Behnaz Saidy |   Emad A. Rakha |   Andrew R. Green |   Ian O. Ellis |   Stewart G. Martin |   
Sarah J. Storr
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Division of Cancer and Stem Cells, 
Nottingham Breast Cancer Research 
Centre, School of Medicine, University 
of Nottingham Biodiscovery Institute, 
Nottingham, UK
Correspondence
Sarah J. Storr, Division of Cancer and Stem 
Cells, Nottingham Breast Cancer Research 
Centre, School of Medicine, University 
of Nottingham Biodiscovery Institute, 
University Park, Nottingham, NG7 2RD, UK.
Email: sarah.storr@nottingham.ac.uk
Funding information
The University of Nottingham's Research 
Vision funded SJS as a Nottingham Research 
Fellow.
Abstract
Cyclin-dependent kinase 5 (Cdk5) is an atypical member of the cyclin-dependent ki-
nase family and functions as a serine/threonine kinase that can be activated by non-
cyclin binding activators p35 or p39. Cdk5 expression and activity has been linked 
with the development and progression of cancer; however, its expression in breast 
cancer has not been fully described. Protein expression of Cdk5 was determined in a 
large cohort of early-stage invasive breast cancer tumours (n = 1110) with long-term 
follow-up data using immunohistochemistry. Expression of CDK5 mRNA was as-
sessed in the METABRIC cohort (n = 1980). Low nuclear and cytoplasmic expression 
of Cdk5 expression was significantly associated with shorter breast cancer-specific 
survival (P = .004 and P = .001, respectively). Importantly, low nuclear and cytoplas-
mic expression of Cdk5 remained associated with survival in multivariate analysis, 
including potentially confounding factors (hazard ratio (HR) = 0.612, 95% confidence 
interval (CI) = 0.418-0.896, P = .011 and HR = 0.507, 95% CI = 0.318-0.809, P = .004, 
respectively). In addition, low nuclear and cytoplasmic expression of Cdk5 was sig-
nificantly associated with clinicopathological criteria associated with adverse patient 
prognosis. Low CDK5 mRNA expression was associated with shorter patient survival 
(P = .005) in the METABRIC cohort; no associations between copy gain or loss and 
survival were observed. These data suggest that low Cdk5 expression is associated 
with poor clinical outcome of breast cancer patients and may be of clinical relevance.
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however, it is clear that Cdk5 can play a role in cell types other than 
neurons and in the pathogenesis of certain diseases, such as can-
cer and Alzheimer's disease. Cdk5 functions in the development and 
progression of cancers through modulation of key pathways such as 
DNA repair and cellular migration.
Cdk5 was first described in 1992,1 and its function and numer-
ous substrates have subsequently been described (reviewed in Ref. 
[2]). Monomeric Cdk5 is inactive and requires binding of p35 or p39 
to become activated, and it also functions in a negative feedback 
pathway through phosphorylation of p35 leading to its ubiquitina-
tion and subsequent degradation.3
In neurons, Cdk5 functions in numerous important cellular 
pathways; for example, phosphorylation of apurinic/apyrimidinic 
endonuclease 1 (Ape1) by Cdk5/p35 complexes reduces the AP 
endonuclease activity of Ape1, an enzyme critical in the base ex-
cision repair pathway, to allow DNA damage to accumulate.4 Cdk5 
also phosphorylates focal adhesion kinase (FAK) allowing regulation 
of a microtubule fork that results in neuronal migration.5 In cancer, 
Cdk5 participates in numerous pathways associated with tumour 
progression. Cdk5 can influence cellular migration in cancer, such 
as phosphorylation of FAK, promoting the formation of F-actin 
bundles to facilitate epithelial to mesenchymal transition and motil-
ity.6 In addition, phosphorylation of GIV by Cdk5 is to play a role in 
the migration-proliferation dichotomy,7 and in breast cancer, Cdk5 
phosphorylation of adducin-1 is important for epidermal growth fac-
tor-induced cell migration and invasion.8
In cancer, high Cdk5 protein and mRNA expression is associated 
with clinicopathological features associated with a poor prognosis or 
adverse survival in a number of tumour types. In lung cancer, high 
CDK5 mRNA expression has been associated with survival, and pro-
tein expression is associated with numerous clinicopathological cri-
teria associated with a poor prognosis.9,10
Studies have assessed the association between Cdk5 and sur-
vival; however, this has been in tumour types other than breast. 
In colorectal cancer, high Cdk5 expression is associated with poor 
prognosis,11 and in gastric cancer, low Cdk5 expression has been 
associated with shorter patient survival.12 In breast cancer, Cdk5 
expression has been associated with prognostic factors associ-
ated with worse patient prognosis; however, no association with 
survival was reported.6 We sought to determine the frequency 
of Cdk5 overexpression in a large cohort of early-stage invasive 
breast cancers to determine whether Cdk5 expression was associ-
ated with poor patient survival and test associations with clinico-
pathological criteria.
2  | METHODS
2.1 | Patient cohorts
A total of 1110 early-stage invasive, primary breast cancer patients 
were included in this study and were treated between 1998 and 2006 
at Nottingham University Hospitals. All patients underwent a wide 
local excision or mastectomy, which was determined by disease char-
acteristics or patient choice; this was then followed by radiotherapy, if 
indicated. Oestrogen receptor (ER) positivity/negativity, Nottingham 
Prognostic Index (NPI) value and menopausal status were used to 
determine whether a patient received systemic adjuvant treatment. 
Patients with an NPI index 3.4 or greater were candidates for CMF 
combination chemotherapy (cyclophosphamide, methotrexate and 
5-fluorouracil) if they were ER negative or premenopausal; and hor-
mone therapy if they were ER positive. Breast cancer-specific sur-
vival was calculated as the time between death resultant from breast 
cancer and primary surgery, and the reverse Kaplan-Meier method 
was used to calculate the median patient follow-up as 148 months. 
REMARK criteria were used to report this study.13
The molecular taxonomy of breast cancer international consor-
tium (METABRIC) data series was also used (n = 1980) with infor-
mation about the data set published elsewhere.14 Tumours were 
collected between 1977 and 2005 from five centres in the UK and 
Canada. The reverse Kaplan-Meier method was used to determine 
the median patient follow-up as 141 months. ER-negative and/or 
lymph node-positive patients did not receive adjuvant chemother-
apy, whereas almost all ER-negative and lymph node-positive pa-
tients did. Trastuzumab was not given to any patients with HER2 
overexpression. In brief, RNA and DNA were isolated from samples 
and hybridized to the Affymetrix SNP 6.0 and Illumina HT-12 v3 
platforms for genomic and transcriptional profiling.
2.2 | Immunohistochemistry
Tissue microarrays were used for immunohistochemistry and were 
composed of 0.6 mm tissue cores taken from representative tumour 
areas which were determined using Haematoxylin and eosin-stained 
tissue. Leica Novolink Polymer Detection kit was used according to 
the manufacturers’ instructions and has been described previously15; 
briefly, the slides were heated on a 60°C hotplate for 10 minutes 
prior to deparaffinization and rehydration in xylene, ethanol and then 
water. Tissue was microwaved in 0.01 mol L−1 sodium citrate buffer 
for 10 minutes at 750 W followed by 10 minutes at 450 W. Novolink 
Peroxidase Block was incubated on the tissue for five minutes prior 
to washing with Tris-buffered saline (TBS) and followed by incubation 
with Novolink Protein Block solution. Cdk5 mouse monoclonal anti-
body (Cell Signalling 12134) was incubated on the tissue microarray at 
room temperature for one hour, once diluted 1:500. TBS was used to 
wash the tissue prior to incubation with Novolink Post Primary solu-
tion for 30 minutes followed by washing and incubation with Novolink 
Polymer solution for 30 minutes. The chromogenic substrate for de-
veloping immunohistochemical reactions was 3, 3′diaminobenzidine, 
and tissue was then counterstained with Haematoxylin. Following 
staining, tissue was dehydrated in sequential washes of ethanol and 
xylene before mounting using DPX. A breast tumour composite sec-
tion, comprised of grade one and two early-stage invasive tumours, 
was used as a positive and negative control and was included in each 
staining run; negative controls had primary antibody omitted.
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Slides were assessed following scanning using a Nanozoomer 
Digital Pathology Scanner (Hamamatsu Photonics) at 200× magnifi-
cation. Cytoplasmic staining was manually assessed using an immu-
nohistochemical H-score, where the percentage area of each staining 
intensity (none (0), weak (1), medium (2) or strong (3)) was assessed. 
Nuclear staining was manually assessed in a semi-quantitative man-
ner, where the percentage of tumour cells that demonstrated any in-
tensity of staining was determined. The final H-score was assessed 
multiplying the intensity by the percentage of positive cells.
2.3 | Statistical analyses
IBM SPSS (version 24) was used to conduct statistical analysis. The 
final H-score and CDK5 mRNA expression was stratified into low and 
high expression using X-tile software based on breast cancer-specific 
survival.16 Double assessment was performed in over 30% of cases, 
with, with both assessors blinded to both each other's H-score and the 
clinical outcome of the patients. Intraclass correlation coefficients (sin-
gle measure) were 0.958 and 0.912 for Cdk5 cytoplasmic and nuclear 
scores, respectively, both indicating good concordance between scor-
ers. The Pearson chi-squared test of association enabled assessment 
of the connection between clinicopathological variables and catego-
rized protein expression. The Kaplan-Meier method was used to plot 
survival curves, with significance determined using the log-rank test. 
All differences were considered statistically significant at the level of 
P ≤ .05. DARPP-32 staining and scoring has been reported previously.17
3  | RESULTS
3.1 | Cdk5 expression in invasive breast cancer
Cytoplasmic and nuclear Cdk5 staining varied from strong 
to weak, and representative photomicrographs are shown 
in Figure 1A-C. Nuclear Cdk5 expression was significantly 
F I G U R E  1   Representative photomicrographs of Cdk5 immunohistochemistry demonstrating absence of Cdk5 staining (A), cytoplasmic 
staining of Cdk5 (B), and cytoplasmic/nuclear staining of Cdk5 (C) shown at 100× magnification with a 200× magnification inset box; scale 
bar represents 50 µm. Kaplan-Meier analysis of Cdk5 expression, where the impact of low (grey line) and high (black line) expression within 
the cytoplasm (D) and nucleus (E) are shown. Numbers shown below the Kaplan-Meier survival curves are the number of patients at risk at 
the specified month
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TA B L E  1   The associations between clinicopathological variables and nuclear and cytoplasmic expression of Cdk5 in a large cohort of 
breast cancer patients
 
Cytoplasmic Cdk5 expression Nuclear Cdk5 expression
Low High P value Low High P value
Age
<50 years 289 (26.3%) 70 (6.4%) .748 234 (21.4%) 124 (11.3%) .500
≥50 years 588 (53.6%) 150 (13.7%) 467 (42.6%) 271 (24.7%)
Size
<2.0cm 507 (46.3%) 143 (13.0%) .055 393 (35.9%) 256 (23.4%) .005
≥2.0cm 369 (33.7%) 77 (7.0%) 307 (28.0%) 139 (12.7%)
Grade
1 131 (12.0%) 41 (3.7%) .127 102 (9.3%) 70 (6.4%) .022
2 331 (30.2%) 91 (8.3%) 256 (23.4%) 166 (15.2%)
3 414 (37.8%) 88 (8.0%) 342 (31.2%) 159 (14.5%)
Pleomorphism
1 12 (1.1%) 3 (0.3%) .909 8 (0.7%) 7 (0.6%) .316
2 247 (22.8%) 65 (6.0%) 191 (17.6%) 121 (11.2%)
3 609 (56.1%) 149 (13.7%) 494 (45.6%) 263 (24.3%)
Mitosis
1 398 (36.7%) 113 (10.4%) .224 306 (28.3%) 205 (18.9%) .021
2 170 (15.7%) 41 (3.8%) 137 (12.7%) 74 (6.8%)
3 299 (27.6%) 63 (5.8%) 249 (23.0%) 112(10.3%)
Vascular invasion
Definite 265 (24.2%) 53 (4.8%) .072 210 (19.2%) 107 (9.8%) .308
No/probable 611 (55.7%) 167 (15.2%) 490 (44.7%) 288 (26.3%)
Stage
1 549 (50.1%) 142 (13.0%) .167 440 (40.2%) 251 (22.9%) .780
2 234 (21.4%) 64 (5.8%) 188 (17.2%) 109 (10.0%)
3 92 (8.4%) 14 (1.3%) 71 (6.5%) 35 (3.2%)
NPI
Good (≤3.4) 274 (25.0%) 85 (7.8%) .026 208 (19.0%) 151 (13.8%) .015
Intermediate 
(3.41-5.4)
444 (40.6%) 110 (10.1%) 370 (33.9%) 183 (16.7%)
Poor (>5.4) 156 (14.3%) 25 (2.3%) 121 (11.1%) 60 (5.5%)
ER status
Negative 186 (16.9%) 38 (3.5%) .186 160 (14.6%) 64 (5.8%) .009
Positive 691 (62.9%) 183 (16.7%) 542 (49.4%) 331 (30.2%)
PgR status
Negative 373 (36.2%) 83 (8.1%) .103 303 (29.5%) 153 (14.9%) .243
Positive 445 (43.2%) 128 (12.4%) 360 (35.0%) 212 (20.6%)
HER2 status
Negative 748 (72.3%) 192 (18.6%) .769 603 (58.4%) 336 (32.5%) .628
Positive 76 (7.4%) 18 (1.7%) 58 (5.6%) 36 (3.5%)
Triple-negative status
Negative 728 (67.6%) 189 (17.5%) .365 572 (53.2%) 344 (32.0%) .015
Positive 132 (12.3%) 28 (2.6%) 116 (10.8%) 44 (4.1%)
Note: The P values shown in the table are resultant from Pearson's chi-squared test of association; P < .05 are highlighted in bold. NPI is Nottingham 
Prognostic Index, ER is oestrogen receptor, and PgR is progesterone receptor.
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correlated with cytoplasmic Cdk5 expression (P < .001, r2 = .569). 
Nuclear Cdk5 expression had a median H-score of 5 and ranged 
from 0 to 85; an X-tile calculated cut point of H-score 9 was 
used, and 63.9% of cases (710/1110) demonstrated low expres-
sion. Cytoplasmic Cdk5 expression had a median H-score of 
105 and ranged from 0 to 240; an X-tile calculated cut point of 
H-score 159 was used, and 50.6% of cases (562/1110) demon-
strated low expression.
3.2 | Cdk5 expression and 
clinicopathological parameters
Associations between cytoplasmic and clinicopathological variables 
and nuclear Cdk5 expression were assessed (Table 1). Low nuclear 
Cdk5 expression was significantly associated with larger tumour 
size (χ2 = 7.858, df = 1, P = .005), higher tumour grade (χ2 = 7.630, 
df = 2, P = .022), mitosis (χ2 = 7.702, df = 2, P = .021), worse NPI 
value (χ2 = 8.386, df = 2, P = .015), ER-negative tumours (χ2 = 6.754, 
df = 1, P = .009) and triple receptor-negative tumours (χ2 = 5.927, 
df = 1, P = .015; Table 1). Low cytoplasmic expression of Cdk5 was 
significantly associated with a higher NPI values (χ2 = 7.334, df = 2, 
P = .026; Table 1).
3.3 | Cdk5 expression and breast cancer-
specific survival
Both low nuclear and cytoplasmic expressions of Cdk5 were as-
sociated with adverse breast cancer-specific survival (P = .004 
and P = .001, respectively; Figure 1D,E). Low nuclear Cdk5 ex-
pression was significantly associated with survival (hazard 
ratio (HR) = 0.612, 95% confidence interval (CI) = 0.418-0.896, 
P = .011) when confounding prognostic factors were included in 
multivariate analysis (including tumour size, tumour grade, stage, 
NPI, ER status, PR status, HER2 status and vascular invasion [all 
with individual log-rank statistics of P < .001]). Low cytoplasmic 
Cdk5 expression also remained significantly associated with poor 
survival (HR = 0.507, 95% CI = 0.318-0.809, P = .004) when the 
same potentially confounding prognostic factors were included in 
the multivariate analysis.
3.4 | Cdk5 expression and ER status
Cdk5 expression is association with survival was further assessed in 
ER-positive and negative disease. Cytoplasmic expression of Cdk5 
was significantly associated with survival of ER-positive patients 
F I G U R E  2   Kaplan-Meier analysis of cytoplasmic Cdk5 protein expression in oestrogen receptor (ER)-positive disease (A) and ER-negative 
disease (B); and nuclear Cdk5 expression in ER-positive disease (C) and ER-negative disease (D), where low expression (grey line) and high 
expression (black line) are shown
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(P = .002), but not ER-negative patients (P = .245; Figure 2A,B). There 
was no association between nuclear Cdk5 expression and patient 
survival in ER-positive or negative subgroups (P = .079 and P = .065, 
respectively; Figure 2C,D).
3.5 | Cdk5 expression and expression of DARPP-32
As Cdk5 is linked with DARPP-32, we assessed for correlation between 
Cdk5 and previously determined DARPP-32 expression.17 Cytoplasmic 
Cdk5 expression was statistically correlated with cytoplasmic DARPP-
32 expression, although demonstrating a weak biological association 
(P = .004, r2 = .090). A similar finding was observed between nuclear 
DARPP-32 and nuclear Cdk5 expression (P = .001, r2 = 0.103).
3.6 | CDK5 mRNA expression and patient survival
Expression of CDK5 mRNA was assessed for associations with avail-
able clinicopathological data (Table 2); high CDK5 mRNA expression 
was significantly associated with higher tumour grade (χ2 = 12.898, 
df = 2, P = .002), luminal B PAM50 subtype (χ2 = 88.278, df = 5, 
P < .001), ER-positive disease (χ2 = 8.588, df = 1, P = .003) and 
HER2-negative disease (χ2 = 9.922, df = 1, P = .002). Low expres-
sion of CDK5 mRNA was significantly associated with shorter patient 
survival (P = .005; Figure 3A). No association between CDK5 copy 
gain or copy loss with patient survival was observed (Figure 3B,C). 
CDK5 mRNA expression was associated with adverse survival in ER-
positive patients (P = .027), but not ER-negative patients (P = .231; 
Figure 4A,B).
4  | DISCUSSION
In the current study, we demonstrate that, in a large cohort of breast 
cancer patients, low nuclear and cytoplasmic expression of Cdk5 
is significantly associated with adverse disease-specific survival 
(P = .004 and P = .001, respectively). Importantly, low nuclear and 
cytoplasmic Cdk5 expression was significantly associated with sur-
vival in multivariate assessment, when potentially confounding fac-
tors were included (P = .011 and P = .004, respectively). In addition 
to protein expression, low CDK5 mRNA expression was associated 
with shorter patient survival in the METABRIC cohort (P = .005).
Studies have assessed the expression of Cdk5 and its associa-
tion with survival in cancer; however, this has been in tumour types 
other than breast. In gastric cancer, low Cdk5 expression has been 
associated with adverse survival in 240 patient specimens.12 It is 
important to note that the current study assessed Cdk5 expression, 
which is not an indication of Cdk5 activity. If Cdk5 expression is 
directly linked with protein activity in breast cancer, then this study 
indicates that a Cdk5 inhibition strategy may not be appropriate.
A number of studies have assessed levels of CDK5 mRNA and 
associations with survival in breast cancer. High expression of 
CDK5 mRNA has been shown to be associated with adverse me-
tastasis-free survival in a large study of 456 patients; patient clin-
icopathological variables and breast cancer-specific survival were 
not described, so a direct comparison with the current study can-
not be made.18 Furthermore, using a bioinformatics data mining 
process, CDK5 mRNA expression was not associated with overall 
survival in a study containing 1402 breast cancer patients.10 In 
the current study, low CDK5 mRNA expression is associated with 
shorter breast cancer-specific survival of a large well-annotated 
cohort of breast cancer patients (P = .005). In addition to breast 
cancer, CDK5 mRNA expression is important in other tumour 
types; in blood cancers, low CDK5 mRNA expression has been 
shown to be associated with adverse survival (n = 53) and high 
CDK5 expression has been associated with shorter overall survival 
in lung cancer.10
Cdk5 has been shown to play an important role in numer-
ous pathways linked with cancer, with low and high expression 
TA B L E  2   Associations between available clinicopathological 
variables and CDK5 mRNA expression in the METABRIC cohort
 
CDK5 mRNA expression
Low High P value
Grade
1 141 (7.5%) 29 (1.5%) .002
2 548 (29.0%) 222 (11.7%)
3 661 (34.9%) 291 (15.4%)
Stage
1 374 (25.7%) 127 (8.7%) .544
2 589 (40.5%) 236 (16.2%)
3 89 (6.1%) 29 (2.0%)
4 7 (0.5%) 3 (0.2%)
ER status
Negative 365 (18.4%) 109 (5.5%) .003
Positive 1055 (53.3%) 451 (22.8%)
HER2 status
Negative 1222 (61.7%) 511 (25.8%) .002
Positive 198 (10.0%) 49 (2.5%)
PgR status
Negative 671 (33.9%) 269 (13.6%) .754
Positive 749 (37.8%) 291 (14.7%)
PAM50 subtype
Basal 240 (12.1%) 89 (4.5%) <.001
HER2 185 (9.3%) 55 (2.8%)
LumA 535 (27.0%) 183 (9.2%)
LumB 278 (14.0%) 210 (10.6%)
NC 5 (0.3%) 1 (0.1%)
Normal 177 (8.9%) 22 (1.1%)
Note: The P values shown in the table are resultant from Pearson's 
chi-squared test of association, and P < .05 are highlighted in bold. ER is 
oestrogen receptor, and PgR is progesterone receptor.
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associated with survival and or clinicopathological criteria depen-
dent upon tumour type. In breast cancer, high expression of Cdk5, 
determined by immunoblotting, is associated with ER-negative 
tumours and basal-like tumours in 108 patients; however, no 
information on survival was available in this study.6 In the cur-
rent study, we also demonstrated an association with ER status, 
with low nuclear Cdk5 expression associated with ER-positive 
tumours. In addition, low cytoplasmic Cdk5 expression was as-
sociated with shorter survival of ER-positive patients (P = .002), 
but not ER-negative patients. This association was also observed 
with CDK5 mRNA expression and survival of ER-positive patients 
in the METABRIC cohort (P = .027).
F I G U R E  3   Kaplan-Meier analysis 
of CDK5 expression (A) copy gain (B) 
and copy loss (C). In panel (A), the low 
expression (grey line) and high expression 
(black line) are shown. In panel (B), the 
black line indicates copy gain, and in panel 
C, the black line indicates copy loss
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5  | CONCLUSION
Low nuclear and cytoplasmic expression of Cdk5 is associated with 
poor breast cancer-specific survival of breast cancer patients; in ad-
dition to survival, Cdk5 expression was associated with a number of 
clinicopathological criteria indicative of poor prognosis. Importantly, 
low nuclear and cytoplasmic Cdk5 expression remained signifi-
cantly associated with survival in multivariate assessment, when 
potentially confounding factors were included (P = .011 and P = .004 
respectively). In addition to protein expression, low CDK5 mRNA 
expression was associated with shorter survival of patients in the 
METABRIC cohort. These findings warrant further investigation in 
larger patient cohorts, but indicate that Cdk5 expression may be of 
clinical relevance in breast cancer.
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